• Prioritizing compounds for further screening according to activity in the primary HTS assay, the de-facto approach for ranking hits both in academia and in the industry. The underlying assumption here is that if a compound is very active in the primary screen, it is likely to have similar bioactivity in the confirmatory screen as well.